Crispr Therapeutics AG (CRSP) Expected to Announce Earnings of -$0.92 Per Share
Brokerages expect that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings of ($0.92) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($1.01). Crispr Therapeutics posted earnings per share of ($0.82) in the same quarter last year, which suggests a negative year-over-year growth rate of 12.2%. The company is scheduled to report its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Crispr Therapeutics will report full year earnings of ($3.82) per share for the current year, with EPS estimates ranging from ($4.18) to ($3.17). For the next year, analysts expect that the firm will report earnings of ($4.26) per share, with EPS estimates ranging from ($5.04) to ($3.24). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, April 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.03). The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $1.50 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The business’s revenue for the quarter was down 78.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) EPS.
In other Crispr Therapeutics news, President Rodger Novak sold 85,220 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $40.40, for a total value of $3,442,888.00. Following the completion of the transaction, the president now directly owns 1,024,534 shares in the company, valued at $41,391,173.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $42.03, for a total transaction of $840,600.00. Following the completion of the transaction, the chief executive officer now owns 186,542 shares of the company’s stock, valued at $7,840,360.26. The disclosure for this sale can be found here. Company insiders own 37.70% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. Versant Venture Management LLC boosted its stake in shares of Crispr Therapeutics by 17.7% in the 1st quarter. Versant Venture Management LLC now owns 4,248,888 shares of the company’s stock valued at $151,770,000 after purchasing an additional 640,014 shares in the last quarter. ARK Investment Management LLC boosted its position in Crispr Therapeutics by 52.7% during the 1st quarter. ARK Investment Management LLC now owns 2,023,017 shares of the company’s stock worth $72,262,000 after acquiring an additional 697,907 shares during the last quarter. Wellington Management Group LLP boosted its position in Crispr Therapeutics by 72.9% during the 1st quarter. Wellington Management Group LLP now owns 1,454,630 shares of the company’s stock worth $51,959,000 after acquiring an additional 613,192 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new position in Crispr Therapeutics during the 4th quarter worth approximately $16,598,000. Finally, Two Sigma Investments LP boosted its position in Crispr Therapeutics by 25.2% during the 4th quarter. Two Sigma Investments LP now owns 509,572 shares of the company’s stock worth $14,558,000 after acquiring an additional 102,478 shares during the last quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.
Shares of CRSP traded down $1.02 during mid-day trading on Friday, hitting $35.57. The company’s stock had a trading volume of 306,072 shares, compared to its average volume of 378,694. The stock has a market capitalization of $1.94 billion, a P/E ratio of -10.34 and a beta of 3.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 15.84 and a quick ratio of 15.84. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $73.88.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.